25rhk144 10.3205/25rhk144 urn:nbn:de:0183-25rhk1447 Meeting Abstract Alten Alten Rieke R

Schlosspark Klinik, Department of Internal Medicine and Rheumatology, Berlin

author Burmester Burmester Gerd-Rüdiger GR

Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin

author Zinke Zinke Silke S

Rheumatologische Schwerpunktpraxis Berlin, Berlin

author Sieburg Sieburg Maren M

Rheumatologische Facharztpraxis, Magdeburg

author Riegel Riegel Kathrin K

Eli Lilly and Company, Indianapolis

author Kill Kill Angela A

Eli Lilly and Company, Indianapolis

author Gerwien Gerwien Jens J

Eli Lilly and Company, Indianapolis

author Ogwu Ogwu Samuel S

Eli Lilly and Company, Indianapolis

author Sanden Sanden Louis Paul LP

Eli Lilly and Company, Indianapolis

author Krüger Krüger Klaus K

Rheumatologisches Praxiszentrum, München

author German Medical Science GMS Publishing House

Düsseldorf

610 20250917 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0627 144 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie 53. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 39. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2025 Rheumatoide Arthritis Wiesbaden 20250917 20250920 RA.21 TextIntroduction: RA-BE-REAL is a prospective, multinational, observational study, evaluating time until discontinuation following either baricitinib (BARI), biologic disease-modifying antirheumatic drugs (b) DMARDs or other targeted synthetic (ts) DMARDs treatment for the first time. This analysis covers German data.Methods: Two cohorts were evaluated: treatment with BARI (cohort-A), or any other b/tsDMARDs (cohort-B). Disease activity was assessed by clinical disease activity index (CDAI), physician function by Health Assessment Questionnaire Disability Index (HAQ-DI), and pain by Visual Analogue Scale (VAS). No statistical comparisons were conducted. Time to discontinuation and discontinuation rates were estimated descriptively.Results: This analysis included 421 (cohort-A; N= 240 and cohort-B; N=181) 3-year data for patients with RA in Germany. In cohort-A, 209 patients received BARI 4mg, and 31 received BARI 2 mg. Cohort-A mean disease duration (standard deviation) of 8.4 (7.3) years was longer than in cohort-B (7.8. [9.4]). Patients previously treated with b/tsDMARDs constituted 48.0% of cohort-A and 32.6% of cohort-B. Monotherapy was more frequent in cohort-A patients (60.8% vs 46.4%) (Table 1 ). At 36-months, 51.1% (cohort-A) vs 47.2% (cohort-B) of patients achieved low disease activity (CDAI: 2.9-10.0), and 26.7% vs 26.0% achieved remission (CDAI ≤2.8), respectively. Fewer patients in cohort-A (43.1%) discontinued treatment at 36-months vs cohort-B (56.4%). Main reasons for discontinuation were primary non-response (cohort-A; n=13 [5.4%]), cohort-B; n=29 [16.0%]) and secondary loss of response (cohort-A; n=30 [12.6%]) and cohort-B; n=30 [16.6%])* (Table 2 ).Conclusion: Patients in cohort-A (BARI) had longer disease duration, more frequent use of previous b/tsDMARDs, and more patients in monotherapy. However, fewer discontinuations with less primary and secondary lack of efficacy for up to 3 years were observed in cohort-A. Furthermore, cohort-A showed better effectiveness (CDAI), with a higher percentage of patients achieving low disease activity than cohort-B.Disclosures: RA reports payment or honoraria for speakers bureaus from: AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB; consulting fees from: AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB; and support for attending meetings and/or travel from: AbbVie, Amgen, BMS, Celltrion, Chugai, Galapagos, Gilead, Janssen, Eli Lilly and Company, Mylan/Viatris, Novartis, Pfizer, Roche, and UCB. GB reports speakers bureau: Alfasigma, Abbvie, Galapagos, Eli Lilly and Company, and Pfizer, Consultant of: Abbvie, Galapagos, and Alfasigma. SZ reports fees for studies and lecture from: Abbvie, GSK, Johnson & Johnson, Lilly, and UCB. MS reports COI for Abbvie, AstraZeneca, Böhringer Ingelheimer, BMS, Celltrion, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB. KR, AK, JGG, SO, and LS are employees and minor shareholders of Eli Lilly and Company. KK reports payment or honoraria from Lilly and Company as well as consultation fees and clinical trial payments from Eli Lilly and Company. 11

Table 1: Sociodemographic and clinical characteristics of German patients with RA included in the RA-BE-REAL study.

22

Table 2: Discontinuation rates and reasons for discontinuation of German RA patients included in the RA-BE-REAL study at 36 months*.

2 0 0 0